COMMUNIQUÉS West-GlobeNewswire

ALX Oncology to Present at Upcoming Investor Conferences in Q1 2026
19/02/2026
SOUTH SAN FRANCISCO, Calif., Feb. 19, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. ("ALX Oncology”; Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat [...]
Leading Scientists Demonstrate How Seer’s Proteograph Product Suite Advances Cardiovascular and Neurodegenerative Research at US HUPO 2026
19/02/2026
Nathan Basisty, Sasha Singh, Bruce Wilcox, and Mozhgan Boroumand among scientific leaders presenting unique proteomics-enabled biological insights REDWOOD CITY, Calif., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Seer, Inc. ( [...]
Orchestra BioMed to Participate in Upcoming Institutional Investor Conferences
19/02/2026
NEW HOPE, Pa., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) (“Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through [...]
Veru to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
19/02/2026
MIAMI, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory [...]
InterCure Announces Preliminary Estimated 2025 Revenue of NIS 265 Million, Positive Adjusted EBITDA and Cash of NIS 43 Million
19/02/2026
InterCure reports preliminary estimated revenue of NIS 265 million for 2025 and positive Adjusted EBITDA, marking its twelfth consecutive half-year of positive Adjusted EBITDA. Revenue for 2025 represents an increase of [...]
Kane Biotech Expands Commercial Activities in the United States
19/02/2026
WINNIPEG, Manitoba, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (“Kane Biotech” or the “Company”) today announces that it has signed non-exclusive distribution/sales agreements for its revyve ® [...]
Reunion Neuroscience to Participate in Upcoming Investor Conferences
19/02/2026
MORRISTOWN, N.J., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Reunion Neuroscience, Inc., a clinical-stage biopharmaceutical company committed to revolutionizing the treatment of underserved mental health disorders through the [...]
NovaBridge Appoints Biotech Leader, Emmett T. Cunningham, Jr, MD, PhD, MPH, as Vice Chairman of the Board to Further Accelerate Global Biotech Platform
19/02/2026
Appointment is a positive endorsement of NovaBridge’s unique hub-and-spoke model and focus on creating shareholder value by accelerating the development of transformative medicines for patients around the world As a [...]
ALX Oncology to Report Fourth Quarter and Full Year 2025 Financial Results on February 27, 2026
19/02/2026
SOUTH SAN FRANCISCO, Calif., Feb. 19, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. ("ALX Oncology"; Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat [...]
Drug-Delivery Breakthroughs, Cross-Indication Research Accelerate New Momentum in CNS and Oncology Development
19/02/2026
AUSTIN, Texas, Feb. 19, 2026 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage : Biotechnology mergers and acquisitions (M&As) are increasingly shaped by a clear strategic evolution. Pharmaceutical companies are [...]
Protara Therapeutics to Participate in Upcoming Investor Conferences
19/02/2026
NEW YORK, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that [...]
Q-Sera announces the first launch of blood collection tubes using its patented Rapclot technology in Japan, opening opportunities for additional global partnerships
19/02/2026
MELBOURNE, Australia , Feb. 19, 2026 (GLOBE NEWSWIRE) -- Q-Sera Pty Ltd, an Australian venture-backed company, today announced the first product launch of its patented evacuated blood collection technology, with the [...]
Reacta Healthcare Appoints Richard Nagle as Chair of Board of Directors
19/02/2026
Pharma, Biotech and Medtech Sector Leader and Entrepreneur to Drive Further Growth and Strategic Expansion DEESIDE, United Kingdom, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Reacta Healthcare Ltd, a leading developer of food [...]
Ipsen S.A. publishes its 2025 Consolidated Financial Statements
19/02/2026
Ipsen S.A. publishes its 2025 Consolidated Financial Statements Attachment Ipsen_Consolidated financial statements 2025_GB
Ipsen S.A. publie ses comptes consolidés 2025
19/02/2026
Ipsen S.A. publie ses comptes consolidés 2025 Pièce jointe Ipsen_Comptes Consolidés 2025_FR
Philips publishes its Annual Report 2025
19/02/2026
February 19, 2026 Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today published its Annual Report 2025. Philips’ Annual Report 2025 will be on the agenda of the [...]
Eupraxia Pharmaceuticals Announces Pricing of US$55 Million Public Offering of Common Shares and Pre-Funded Warrants
19/02/2026
VICTORIA, British Columbia, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”) (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary [...]
IBA and Shreeji sign multi‑site agreement for four cyclotrons to expand PET radiopharmaceutical manufacturing across India
19/02/2026
Louvain-la-Neuve, Belgium – 19 February 2026 – IBA (Ion Beam Applications S.A., EURONEXT) , the world leader in particle accelerator technology with a preeminent position in nuclear medicine, and Shreeji (Shreeji [...]
IBA et Shreeji signent un accord pour quatre cyclotrons afin d’étendre la production de radiopharmaceutiques TEP en Inde
19/02/2026
Louvain-la-Neuve, Belgium – 19 février 2026 – IBA (Ion Beam Applications S.A., EURONEXT) , le leader mondial des technologies d'accélérateurs de particules et acteur de premier plan en médecine nucléaire, et Shreeji ( [...]

Pages